PRESS RELEASE : BRAIN Biotech AG: BRAIN actively supports the UN Global Compact

DGAP-News: BRAIN Biotech AG / Key word(s): Sustainability 
BRAIN Biotech AG: BRAIN actively supports the UN Global Compact 
2021-06-08 / 11:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Zwingenberg, Germany, June 8, 2021 
BRAIN actively supports the UN Global Compact 
BRAIN Biotech AG, Germany, now actively supports the UN Global Compact, a voluntary initiative based on company 
commitments to implement universal sustainability principles and to advance United Nations goals such as the 
Sustainable Development Goals (SDGs). With our current products and solutions, we already directly address at least 
five UN sustainability goals. 
BRAIN Biotech AG (BRAIN, ISIN DE0005203947 / WKN 520394) now atively supports the UN Global Compact with its corporate 
responsibility initiative and principles. By joining the UN Global Compact, BRAIN now formally commits to the values of 
the world's largest initiative for corporate social responsibility and thus commits to ten universal principles 
concerning human rights, labour standards, environment and climate as well as the prevention of corruption. 
With the current products and solutions, BRAIN already directly addresses at least five of the UN Sustainable 
Development Goals (SDG): 
  . SDG 2, Zero Hunger: natural compounds for food preservation 
  . SDG 3, Good Health & Well-Being: natural sugar replacement, salt replacement and salt taste enhancers, natural 
    aromas, bioactive plant cosmetic and chronical wound treatment 
  . SDG 6, Clean Water & Sanitation: green mining solutions to replace chemical hazards 
  . SDG 9, Industry, Innovation & Infrastructure: biotechnological production, improving production efficiencies for 
    resource conservation, fermented food from side-streams, microbial CO2 usage 
  . SDG 12, Responsible Consumption & Production: green and urban mining (bio-based recycling) 
Adriaan Moelker, CEO BRAIN Biotech AG, states: "We take pride to support the UN Global Compact, one of the globally 
most important initiatives for the corporate sector to adopt sustainable and socially responsible policies. BRAIN 
develops products and services, which change the way industrial production is done. Our natural and sustainable 
bio-based processes accelerate the economic transformation to a circular economy. In addition, we incorporate 
sustainability aspects and good corporate governance in the daily management of our operations. Acting responsibly is 
elementary for all of BRAIN's stakeholders so that I am personally heading our ESG initiatives. We are currently 
preparing a corporate sustainability report to document our goals and their implementation also under the framework of 
the UN Global Compact." 
 
Disclaimer 
This press release contains forward-looking statements. These statements reflect the current views, expectations, and 
assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. 
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as 
uncertainties that could cause actual results, performance or events to differ materially from those expressed or 
implied in such statements. Numerous factors exist that could influence the future performance by, and future 
developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the 
general economic and competitive environment, risks associated with capital markets, currency exchange rate 
fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and 
regulations, as well as other factors. 
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements. 
 
About BRAIN 
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and 
developer of bio-based products and solutions for nutrition, health and the environment, the company supports the 
biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN 
Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned 
industrial partners as well as an incubator for the development of the company's own highly innovative products. In the 
BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, 
microorganisms and bioactive natural products and the respective distribution. 
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises 
microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology 
portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already 
successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, 
which together with the associated biotechnological production expertise, complete the value chain within the Group. 
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN 
DE0005203947 / WKN 520394). 
About UN Global Compact 
The United Nations Global Compact is a non-binding United Nations pact to encourage businesses and firms worldwide to 
adopt sustainable and socially responsible policies, and to report on their implementation. The UN Global Compact is a 
principle-based framework for businesses, stating ten principles in the areas of human rights, labor, the environment 
and anti-corruption. Under the Global Compact, companies are brought together with UN agencies, labor groups and civil 
society. Cities can join the Global Compact through the Cities Programme. 
Further details at: 
https://www.unglobalcompact.org/what-is-gc 
Contact Investor Relations 
Michael Schneiders 
Head of Investor Relations & Sustainability 
Phone: [phone] 
Email: [e-mail] 
Media Contact 
Dr. Stephanie Konle 
PR & Corporate Communications 
Phone: [phone] 
Email: [e-mail] 
 
Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG) 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-08 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      BRAIN Biotech AG 
              Darmstädter Straße 34-36 
              64673 Zwingenberg 
              Germany 
Phone:        [phone] / 9331-0 
Fax:          [phone] / 9331-11 
E-mail:       [e-mail] 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1205443 
 
End of News   DGAP News Service 
=------------ 

1205443 2021-06-08

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1205443&application_name=news

(END) Dow Jones Newswires

June 08, 2021 05:01 ET (09:01 GMT)